

## CARDIOCOMM SOLUTIONS INC ("EKG-V")

### - Issues Stock Options

CardioComm Solutions, Inc. announced that it has granted 100,000 incentive stock options to Mr. Simi Grosman, an independent member of the Company's board of directors. The options are exercisable at \$0.10 per share for five years from the date of grant, vest equally over 18 months at the end of each three month period from the date of grant and are subject to a four month hold period. The grant of options is subject to the provisions of the Company's Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws.

Mr. Grosman is participating as a member of CardioComm's C4 management team, which is a cardiac monitoring service provided to patients for remote and telemedicine based in-home ECG and arrhythmia reporting. "We value Mr. Grosman's contributions as we continue to expand C4 subscription in Ontario and look to expansion into the USA and overseas," said Etienne Grima, CardioComm's CEO.

CardioComm also previously announced a transaction with MD Primer Inc. ("MDP") for the purchase of hardware and software by CardioComm from MDP. The transaction has been postponed, and the Company will provide a further update if there are changes to the status of the transaction.

### About CardioComm Solutions, Inc.

CardioComm's patented and proprietary technology is used in the wireless and telephone based transmission, receipt and viewing, analyzing and storing of single and multichannel electrocardiograms (EKGs), for arrhythmia diagnosis and management of cardiac patients. The Company's products are sold worldwide through its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time EKG viewer. CardioComm is the first company to provide a real-time means of viewing EKGs over a network (LAN, WAN or Internet). This tool enables EKGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global EKG Management System (GEMS(TM)) and GlobalCardio(TM). CardioComm's software products are compatible with the majority of event loop recorders and ultraportable 12 lead devices. Its software

solutions have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

Etienne Grima, CEO

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

TEL: 1.800.725.6585, ext. 227 Etienne Grima, CEO  
Website: [www.cardiocommsolutions.com](http://www.cardiocommsolutions.com)

---

(c) Market News Publishing Inc. Tel:(604) 689-1101  
All rights reserved. Fax:(604) 689-1106